



Office of the Secretary

UNITED STATES OF AMERICA  
FEDERAL TRADE COMMISSION  
WASHINGTON, D.C. 20580

March 7, 2006

M. Sean Royall, Esq.  
Gibson, Dunn & Crutcher LLP  
1050 Connecticut Avenue, N.W.  
Washington, DC 20036-5306

Re: *Allergan, Inc. and Inamed Corporation*  
*FTC File No. 061 0031, Docket No. C-4156*

Dear Mr. Royall:

This letter notifies Allergan, Inc. ("Allergan") that the Federal Trade Commission has approved the appointment of Mr. Charles A. Riepenhoff, Jr., Managing Director, KPMG LLP, as the Interim Monitor, and has approved the Interim Monitor Agreement by and between KPMG LLP and Allergan Inc. and Inamed Corporation ("Inamed") dated February 17, 2006, pursuant to Paragraph III of the Order to Maintain Assets issued in the above-referenced matter.

In according its approval, the Commission has relied upon the information submitted and representations made by Allergan, Inamed, and KPMG LLP and has assumed them to be accurate and complete.

By direction of the Commission, Commissioner Rosch recused.

Donald S. Clark  
Secretary

cc: W. Stephen Smith, Esq.  
Morrison & Foerster LLP  
2000 Pennsylvania Ave, N.W., Suite 5500  
Washington, DC 20006-1888

Mr. Charles A. Riepenhoff, Jr.  
Managing Director  
KPMG LLP  
303 Peachtree Street, NE, Suite 2000  
Atlanta, GA 30308